New incident report
Incident Report Number: 2020-0462
Registrant Reference Number: 2019-US-028016
Registrant Name (Full Legal Name no abbreviations): The Hartz Mountain Corporation
Address: 400 Plaza Drive
City: Secaucus
Prov / State: New Jersey
Country: USA
Postal Code: 07094-3688
Domestic Animal
Country: UNITED STATES
Prov / State: FLORIDA
PMRA Registration No. PMRA Submission No. EPA Registration No. 2596-139
Product Name: Hartz UltraGuard Pro Flea and Tick Collar
Other (specify)
CollarYes
Unknown
Site: Animal / Usage sur un animal domestique
Animal's Owner
Cat / Chat
Domestic Shorthair
1
Male
3
15
lbs
Skin
>24 hrs <=3 days / >24 h <=3 jours
>24 hrs <=3 days / >24 h <=3 jours
System
Persisted until death
No
No
Died
Treatment / Traitement
(eg. description of the frequency and severity of the symptoms
On 13-Oct-2019 the pet owner applied one Hartz UltraGuard Pro Flea and Tick collar (tetrachlorvinphos, s-methoprene) to the cat. On 16-Oct-2019 the cat suddenly collapsed and died. The product was applied to two other cats in the home that remained asymptomatic. Though the pet owner was interested in pursuing a necropsy it is unknown if one was completed. No further information was received in this case.
Death
Assessment: This product is considered to have a wide margin of safety in cats. If a small amount of product was ingested, only minor oral irritation or gastrointestinal upset resulting in drooling of vomiting would be expected. Sudden onset of collapse and death are not expected and not likely due to product use. Other causes including unknown trauma, underlying cardiac disease and aortic thromboembolism (saddle thrombus) should be considered. The information contained in this report is based on self-reported statements provided to the registrant during telephone interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and cannot form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.